{"entity":{"id":"nct06077760","kind":"trial","name":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (","aka":["INTerpath-002"],"tldr":"A phase 3 trial of Intismeran autogene, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) is a phase 3 interventional study registered as NCT06077760 by Merck Sharp & Dohme LLC, with 868 participants planned, started 2023-12-06 and due to reach its primary completion in 2030-06-25. Interventions recorded: Intismeran autogene, Pembrolizumab, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT06077760","url":"https://clinicaltrials.gov/study/NCT06077760"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc","resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":[],"drugs":["intismeran-autogene","pembrolizumab"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Registry status on 22 September 2026: Active, not recruiting (registry record last updated 18 September 2026; primary completion expected 25 June 2030)."],"nct":"NCT06077760","phase":"3","setting":"A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer (INTerpath-002)","sponsor":"Merck Sharp & Dohme LLC","started":"2023-12-06","startedType":"actual","enrolled":868,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06077760/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}